Table 2.
Multivariate analyses of risk of malignant diseases among biologic users in comparison with matched controls
| All | TNF-α inhibitor 1 users | Adalimumab 2 | Etanercept 3 | Rituximab | ||
|---|---|---|---|---|---|---|
| Biologics | Event, number | 89 | 89 | 8 | 71 | 0 |
| Total person-years | 16650.63 | 16624.36 | 2203.45 | 10363.75 | 26.27 | |
| IR per 1000 (95% CI) | 5.35 (4.23, 6.46) | 5.35 (4.24, 6.47) | 3.63 (1.11, 6.15) | 6.85 (5.26, 8.44) | - | |
| nbDMARDs4 | Event, number | 486 | 485 | 51 | 309 | 1 |
| Total person-years | 65587.93 | 65485.91 | 8763.78 | 41209.78 | 102.02 | |
| IR per 1000 (95% CI) | 7.41 (6.75, 8.07) | 7.41 (6.75, 8.07) | 5.82 (4.22, 7.42) | 7.50 (6.66, 8.33) | 9.80 (0.00, 29.01) | |
| HR (95% CI) | 0.63 (0.49, 0.80) | 0.63 (0.50, 0.81) | 0.61 (0.28, 1.33) | 0.83 (0.62, 1.10) | - | |
| IRR (95% CI) | 0.72 (0.58, 0.90) | 0.72 (0.58, 0.91) | 0.62 (0.30, 1.31) | 0.91 (0.71, 1.18) | - | |
| P-value | 0.0046 | 0.0049 | 0.2147 | 0.4926 | - |
1Includes all patients who have used TNF-α inhibitors, with or without disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids, in comparison with matched controls. 2Use of adalimumab alone, with or without DMARDs or corticosteroids, in comparison with matched controls. 3Use of etanercept alone, with or without DMARDs or corticosteroids, in comparison with matched controls. 4Indicates the event number and total observed person-years of matched subjects from THE nonbiologic DMARDS (nbDMARDs) cohort for each of those using different types of TNF-α inhibitors and rituximab. HR, hazard ratio; IR, incidence rate; IRR, incidence rate ratio.